Abstract 785P
Background
The purpose of this study is to investigate the effect of radiotherapy on programmed death ligand 1 (PD-L1) expression and explore the predictive role of exosomal PD-L1 (ExoPD-L1) in immunotherapy for cervical cancer.
Methods
The consecutive tumor sample of 40 primarily diagnosed CC patients who accepted radical radiotherapy (RT) were collected before and during RT. Blood samples of 37 advanced CC patients who accepted ICIs combination therapy were collected from each participant before and during treatment. Exosomes were identified by Western blot (CD9/TSG101/Calnexin), transmission electron microscope and nanoparticle tracking analysis. ExoPD-L1 detection was conducted by ELISA. The knockout of PD-L1 was conducted via CRISPR/Cas9 assay and the overexpress of PD-L1 was conducted by lentiviral transfection. Lymphocyte were detected by multicolor flow cytometry.
Results
The consecutive detection of PD-L1 showed a dynamic change during RT. Compared with the level before RT, PD-L1 expression elevated in most patients (87.5%) after RT. And the responders (n=18) had elevated ExoPD-L1 level at the first two circles in the ICIs combination therapy (P<0.001). The median follow-up time was 14.13m. The mPFS in increased vs. decreased group: NR vs.11.02m (P=0.025). Continuous blood sampling of mice models also found that effective therapeutic intervention could increase ExoPD-L1 in the early stage. The combination of exosome inhibitor GW4869 and anti-PD-1 further inhibited tumor growth. Mice were injected with external ExoPD-L1OEand ExoPD-L1KO. The results showed that ExoPD-L1OE suppressed body immunity and promoted tumor growth. The results of flow cytometry showed that ExoPD-L1OE inhibited CD8+T cells from releasing interferon-γand granzyme B. And ExoPD-L1OE also suppressed the CD8+T cells proliferation in spleen. The coculture of CD8+T cells and exosomes in vitro also confirmed the above conclusion.
Conclusions
Compared with unstable tumoral PD-L1, ExoPD-L1 can better predict the efficacy of immunotherapy in CC, which was with easy accessibility and continuation. Exosome PD-L1 played an immunosuppressive role by inhibiting the proliferation and functional factor release of CD8+T cell.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11